Research Analysts Set Expectations for ABEO FY2025 Earnings

Abeona Therapeutics Inc. (NASDAQ:ABEO) – Research analysts at HC Wainwright cut their FY2025 earnings estimates for Abeona Therapeutics in a note issued to investors on Thursday, November 13th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings per share of $1.22 for the year, down from their previous estimate of $1.49. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q4 2025 earnings at ($0.42) EPS, Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at $0.03 EPS and FY2026 earnings at ($0.41) EPS.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.17.

ABEO has been the subject of a number of other research reports. Wall Street Zen downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Oppenheimer increased their price target on Abeona Therapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a report on Friday, August 15th. Finally, Weiss Ratings downgraded Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 24th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Abeona Therapeutics Trading Down 0.7%

Shares of ABEO stock opened at $4.48 on Monday. Abeona Therapeutics has a 12-month low of $3.93 and a 12-month high of $7.54. The company has a current ratio of 6.73, a quick ratio of 6.65 and a debt-to-equity ratio of 0.09. The stock’s 50-day moving average price is $5.25 and its 200-day moving average price is $5.94. The stock has a market capitalization of $242.78 million, a price-to-earnings ratio of 6.40 and a beta of 1.45.

Insiders Place Their Bets

In other Abeona Therapeutics news, CFO Joseph Walter Vazzano sold 9,035 shares of the stock in a transaction on Monday, September 29th. The stock was sold at an average price of $5.39, for a total value of $48,698.65. Following the sale, the chief financial officer owned 453,631 shares in the company, valued at $2,445,071.09. This trade represents a 1.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Vishwas Seshadri sold 25,000 shares of Abeona Therapeutics stock in a transaction on Tuesday, September 30th. The stock was sold at an average price of $5.24, for a total value of $131,000.00. Following the sale, the chief executive officer owned 1,190,067 shares of the company’s stock, valued at approximately $6,235,951.08. This trade represents a 2.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 78,612 shares of company stock valued at $410,271. Corporate insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Boone Capital Management LLC bought a new position in Abeona Therapeutics in the second quarter worth approximately $7,126,000. Geode Capital Management LLC lifted its holdings in shares of Abeona Therapeutics by 129.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock worth $6,282,000 after buying an additional 623,243 shares during the period. Cable Car Capital LP purchased a new stake in shares of Abeona Therapeutics in the 3rd quarter worth $3,168,000. JPMorgan Chase & Co. grew its position in shares of Abeona Therapeutics by 255.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 831,132 shares of the biopharmaceutical company’s stock worth $4,721,000 after buying an additional 597,373 shares in the last quarter. Finally, Bank of America Corp DE grew its position in shares of Abeona Therapeutics by 176.7% during the 3rd quarter. Bank of America Corp DE now owns 912,912 shares of the biopharmaceutical company’s stock worth $4,820,000 after buying an additional 583,028 shares in the last quarter. 80.56% of the stock is currently owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.